Biomarker Tied To Success Of GlobeImmune's Therapeutic Hep C Vaccine In Patients With Poor Prognosis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Positive Phase II results for GlobeImmune's immune-boosting hepatitis C vaccine GI-5005 were underscored at the European Association for the Study of the Liver meeting in Vienna April 17 by results from a newly available biomarker test that shows the therapy is most effective at clearing the virus from patients whose genetic status predicts little chance for complete recovery